首页|期刊导航|中国药物经济学|放射性药品经营使用环节监管现状与对策

放射性药品经营使用环节监管现状与对策OA

The Supervision Status and Countermeasures of Radioactive Pharmaceuticals in the Operation and Use Links

中文摘要英文摘要

放射性药品是用于医疗诊断与治疗的特殊药品,但由于其自身半衰期短、储存运输困难等特点,在经营使用环节的监管中面临诸多瓶颈.通过分析放射性药品目前的监管依据,结合经营使用环节中存在的实际问题,有针对性地提出优化建议,旨在提升监管工作的科学性与有效性.研究发现,经营环节存在与《药品经营质量管理规范》(GSP)适配性较差、许可检查难以评判的问题,使用环节存在多部门协同监管不畅、检查职责划分不清的难题.据此,将从法律法规的修订完善、人才配置的适度优化、跨部门协同检查的机制搭建 3 个方面提出应对策略,为放射性药品的高质量发展提供有力的制度保障与监管支撑.

Radioactive pharmaceuticals are special drugs used for medical diagnosis and treatment,yet their inherent characteristics such as short half-life and difficulties in storage and transportation have created tough and blocking points in the supervision of their operation and use links.By analyzing the current regulatory basis for radioactive pharmaceuticals and combining the practical problems in the operation and use links,this paper puts forward targeted optimization suggestions,aiming to improve the scientificity and effectiveness of supervision.The study finds that in the operation link,there exist problems such as poor compatibility with the Good Supply Practice(GSP)and difficulty in evaluating the licensing inspection;the use link is trapped in a dilemma of poor collaborative supervision among multiple departments and unclear division of inspection responsibilities.Accordingly,corresponding countermeasures are proposed from three aspects:revision and improvement of laws and regulations,moderate optimization of talent allocation,and establishment of a cross-departmental collaborative inspection mechanism,so as to provide a strong support for the high-quality development and supervision of radioactive pharmaceuticals.

邢瀚月

云南省食品药品审核查验中心,昆明 650000

医药卫生

放射性药品经营使用质量监管政策探讨优化建议

Radioactive pharmaceuticalsOperation and useQuality supervisionPolicy discussionOptimization suggestions

《中国药物经济学》 2026 (6)

115-119,5

10.12010/j.issn.1673-5846.2026.06.023

评论